ArticleRespirology case reports2025
Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer.Respirology case reports · 2025Article
- Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab.Respiratory medicine case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regorafenib, a multi-targeted tyrosine kinase inhibitor (TKI), is indicated for refractory colorectal carcinoma, gastrointestinal stromal tumours (GIST), and hepatocellular carcinoma (HCC). We present a case involving a 66-year-old male patient with refractory colorectal cancer who developed interstitial pneumonia as a consequence of regorafenib therapy. Three months following the initiation of regorafenib administration, a chest computed tomography scan revealed bilateral ground-glass opacities, a characteristic finding in interstitial lung disease. This case illustrates a relatively rapid progression of regorafenib-induced interstitial lung disease following its radiographic manifestation. Clinicians should remain vigilant for this potential pulmonary toxicity in patients receiving regorafenib, even with an apparently short latency period after treatment commencement. Early recognition and prompt intervention are crucial in managing this adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.